个人中心 - 老虎社区

Terrorlim

IP属地：未知

帖子 · 1帖子 · 1
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- TerrorlimTerrorlim
  ·2021-07-21
  Yeah
  EXCLUSIVE: Celularity's CEO On 'One-Size-Fits-All' Product, Palantir Connection<blockquote>独家：Celularity首席执行官谈“一刀切”产品Palantir Connection</blockquote>
  FormerPepsiCo Inc PEPpresident andApple IncAAPLCEOJohn Sculleyraved about Celularity IncCELUMonday o
  EXCLUSIVE: Celularity's CEO On 'One-Size-Fits-All' Product, Palantir Connection<blockquote>独家：Celularity首席执行官谈“一刀切”产品Palantir Connection</blockquote>
  950 评论
  2
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3585692776043544","uuid":"3585692776043544","gmtCreate":1622598973796,"gmtModify":1626879715736,"name":"Terrorlim","pinyin":"terrorlim","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/fe3c53ba1d6834839da488e14e9c99a8","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":176818927,"gmtCreate":1626875863169,"gmtModify":1633770204249,"author":{"id":"3585692776043544","authorId":"3585692776043544","name":"Terrorlim","avatar":"https://static.tigerbbs.com/fe3c53ba1d6834839da488e14e9c99a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585692776043544","idStr":"3585692776043544"},"themes":[],"htmlText":"Yeah","listText":"Yeah","text":"Yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/176818927","repostId":"1121414767","repostType":4,"repost":{"id":"1121414767","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1626871035,"share":"https://www.laohu8.com/m/news/1121414767?lang=zh_CN&edition=full","pubTime":"2021-07-21 20:37","market":"us","language":"en","title":"EXCLUSIVE: Celularity's CEO On 'One-Size-Fits-All' Product, Palantir Connection<blockquote>独家：Celularity首席执行官谈“一刀切”产品Palantir Connection</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1121414767","media":"Benzinga","summary":"FormerPepsiCo Inc PEPpresident andApple IncAAPLCEOJohn Sculleyraved about Celularity IncCELUMonday o","content":"<p>Former<b>PepsiCo Inc</b>&nbsp;PEPpresident and<b>Apple Inc</b>AAPLCEO<b>John Sculley</b>raved about&nbsp;<b>Celularity Inc</b>CELUMonday on&nbsp;Benzinga's YouTube show \"Power Hour.\"</p><p><blockquote>前者<b>百事可乐公司</b>PEP总裁和<b>苹果公司</b>AAPLCEO<b>约翰·斯卡利</b>赞不绝口<b>细胞公司</b>Benzinga的YouTube节目“Power Hour”中的CELUMonday。</blockquote></p><p> Celularity founder and CEO<b>Robert Harini</b>appeared on&nbsp;\"Power Hour\"&nbsp;for an exclusive interview Tuesday.</p><p><blockquote>Celularity创始人兼首席执行官<b>罗伯特·哈里尼</b>周二出现在“权力时刻”接受独家采访。</blockquote></p><p> Celularity went public via special purpose acquisition company&nbsp;<a href=\"https://laohu8.com/S/GXGX\">GX Acquisition</a> Corp. on July 16.</p><p><blockquote>Celularity通过特殊目的收购公司上市<a href=\"https://laohu8.com/S/GXGX\">GX收购</a>公司于7月16日。</blockquote></p><p> Celularity focuses on delivering&nbsp;cellular medicines derived from the postpartum human placenta, Harini told Benzinga.</p><p><blockquote>Harini告诉Benzinga，Celularity专注于提供源自产后人类胎盘的细胞药物。</blockquote></p><p> Sculley is a&nbsp;founding director and vice chairman of the board at Cellularity.</p><p><blockquote>斯卡利是Cellularity的创始董事兼董事会副主席。</blockquote></p><p> Harini said he's fortunate to work on the noble pursuit of transforming living cells into medicine with Sculley. Harini went on to talk more about Sculley,&nbsp;an award he received&nbsp;from<b>Pope Francis</b>and more.</p><p><blockquote>哈里尼说，他很幸运能与斯卡利一起致力于将活细胞转化为药物的崇高追求。哈里尼接着更多地谈论了斯卡利，他从<b>教皇弗朗西斯</b>还有更多。</blockquote></p><p> <b>Key Highlights:</b></p><p><blockquote><b>主要亮点：</b></blockquote></p><p> <ul>  <li>The human placenta is \"nature's stem cell factory.\"&nbsp;Celularity uses&nbsp;the placenta to produce a product that is \"<a href=\"https://laohu8.com/S/AONE.U\">one</a>-size-fits-all.\"</li>  <li>Celularity uses<b>Palantir Technologies Inc</b>PLTR 0.05%to enhance the quality of its products. Palantir sought out the partnership because of its&nbsp;deep interest in biological science and the health care industry.</li>  <li>One great future opportunity will be to find ways to mitigate the degenerative changes that occur with aging.&nbsp;Cellular biology is \"here to stay.\"</li>  <li>Harini developed his passion after being&nbsp;intrigued by the possibility for&nbsp;stem cells to be used as&nbsp;a tool for restoring function in a damaged brain.</li>  <li>He believes Celularity's future products will have the quality and economics to help lead the industry.</li> </ul> <b>CELU Price Action:</b>Celularity shares gained 4.05% Tuesday, closing at $21.85.</p><p><blockquote><ul><li>人类胎盘是“大自然的干细胞工厂”。Celularity利用胎盘生产一种产品<a href=\"https://laohu8.com/S/AONE.U\">一</a>-一刀切。”</li><li>细胞性用途<b>Palantir技术公司</b>PLTR 0.05%以提高其产品质量。Palantir寻求合作伙伴关系是因为它对生物科学和医疗保健行业有着浓厚的兴趣。</li><li>未来的一个很好的机会将是找到减轻随着衰老而发生的退行性变化的方法。细胞生物学将“留在这里”。</li><li>Harini对干细胞被用作恢复受损大脑功能的工具的可能性感兴趣后，产生了他的热情。</li><li>他相信Celularity未来的产品将具有帮助引领行业的质量和经济性。</li></ul><b>CELU价格走势：</b>Celularity股价周二上涨4.05%，收于21.85美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EXCLUSIVE: Celularity's CEO On 'One-Size-Fits-All' Product, Palantir Connection<blockquote>独家：Celularity首席执行官谈“一刀切”产品Palantir Connection</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEXCLUSIVE: Celularity's CEO On 'One-Size-Fits-All' Product, Palantir Connection<blockquote>独家：Celularity首席执行官谈“一刀切”产品Palantir Connection</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-07-21 20:37</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>Former<b>PepsiCo Inc</b>&nbsp;PEPpresident and<b>Apple Inc</b>AAPLCEO<b>John Sculley</b>raved about&nbsp;<b>Celularity Inc</b>CELUMonday on&nbsp;Benzinga's YouTube show \"Power Hour.\"</p><p><blockquote>前者<b>百事可乐公司</b>PEP总裁和<b>苹果公司</b>AAPLCEO<b>约翰·斯卡利</b>赞不绝口<b>细胞公司</b>Benzinga的YouTube节目“Power Hour”中的CELUMonday。</blockquote></p><p> Celularity founder and CEO<b>Robert Harini</b>appeared on&nbsp;\"Power Hour\"&nbsp;for an exclusive interview Tuesday.</p><p><blockquote>Celularity创始人兼首席执行官<b>罗伯特·哈里尼</b>周二出现在“权力时刻”接受独家采访。</blockquote></p><p> Celularity went public via special purpose acquisition company&nbsp;<a href=\"https://laohu8.com/S/GXGX\">GX Acquisition</a> Corp. on July 16.</p><p><blockquote>Celularity通过特殊目的收购公司上市<a href=\"https://laohu8.com/S/GXGX\">GX收购</a>公司于7月16日。</blockquote></p><p> Celularity focuses on delivering&nbsp;cellular medicines derived from the postpartum human placenta, Harini told Benzinga.</p><p><blockquote>Harini告诉Benzinga，Celularity专注于提供源自产后人类胎盘的细胞药物。</blockquote></p><p> Sculley is a&nbsp;founding director and vice chairman of the board at Cellularity.</p><p><blockquote>斯卡利是Cellularity的创始董事兼董事会副主席。</blockquote></p><p> Harini said he's fortunate to work on the noble pursuit of transforming living cells into medicine with Sculley. Harini went on to talk more about Sculley,&nbsp;an award he received&nbsp;from<b>Pope Francis</b>and more.</p><p><blockquote>哈里尼说，他很幸运能与斯卡利一起致力于将活细胞转化为药物的崇高追求。哈里尼接着更多地谈论了斯卡利，他从<b>教皇弗朗西斯</b>还有更多。</blockquote></p><p> <b>Key Highlights:</b></p><p><blockquote><b>主要亮点：</b></blockquote></p><p> <ul>  <li>The human placenta is \"nature's stem cell factory.\"&nbsp;Celularity uses&nbsp;the placenta to produce a product that is \"<a href=\"https://laohu8.com/S/AONE.U\">one</a>-size-fits-all.\"</li>  <li>Celularity uses<b>Palantir Technologies Inc</b>PLTR 0.05%to enhance the quality of its products. Palantir sought out the partnership because of its&nbsp;deep interest in biological science and the health care industry.</li>  <li>One great future opportunity will be to find ways to mitigate the degenerative changes that occur with aging.&nbsp;Cellular biology is \"here to stay.\"</li>  <li>Harini developed his passion after being&nbsp;intrigued by the possibility for&nbsp;stem cells to be used as&nbsp;a tool for restoring function in a damaged brain.</li>  <li>He believes Celularity's future products will have the quality and economics to help lead the industry.</li> </ul> <b>CELU Price Action:</b>Celularity shares gained 4.05% Tuesday, closing at $21.85.</p><p><blockquote><ul><li>人类胎盘是“大自然的干细胞工厂”。Celularity利用胎盘生产一种产品<a href=\"https://laohu8.com/S/AONE.U\">一</a>-一刀切。”</li><li>细胞性用途<b>Palantir技术公司</b>PLTR 0.05%以提高其产品质量。Palantir寻求合作伙伴关系是因为它对生物科学和医疗保健行业有着浓厚的兴趣。</li><li>未来的一个很好的机会将是找到减轻随着衰老而发生的退行性变化的方法。细胞生物学将“留在这里”。</li><li>Harini对干细胞被用作恢复受损大脑功能的工具的可能性感兴趣后，产生了他的热情。</li><li>他相信Celularity未来的产品将具有帮助引领行业的质量和经济性。</li></ul><b>CELU价格走势：</b>Celularity股价周二上涨4.05%，收于21.85美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CELU":"Celularity Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121414767","content_text":"FormerPepsiCo Inc PEPpresident andApple IncAAPLCEOJohn Sculleyraved about Celularity IncCELUMonday on Benzinga's YouTube show \"Power Hour.\"\nCelularity founder and CEORobert Hariniappeared on \"Power Hour\" for an exclusive interview Tuesday.\nCelularity went public via special purpose acquisition company GX Acquisition Corp. on July 16.\nCelularity focuses on delivering cellular medicines derived from the postpartum human placenta, Harini told Benzinga.\nSculley is a founding director and vice chairman of the board at Cellularity.\nHarini said he's fortunate to work on the noble pursuit of transforming living cells into medicine with Sculley. Harini went on to talk more about Sculley, an award he received fromPope Francisand more.\nKey Highlights:\n\nThe human placenta is \"nature's stem cell factory.\" Celularity uses the placenta to produce a product that is \"one-size-fits-all.\"\nCelularity usesPalantir Technologies IncPLTR 0.05%to enhance the quality of its products. Palantir sought out the partnership because of its deep interest in biological science and the health care industry.\nOne great future opportunity will be to find ways to mitigate the degenerative changes that occur with aging. Cellular biology is \"here to stay.\"\nHarini developed his passion after being intrigued by the possibility for stem cells to be used as a tool for restoring function in a damaged brain.\nHe believes Celularity's future products will have the quality and economics to help lead the industry.\n\nCELU Price Action:Celularity shares gained 4.05% Tuesday, closing at $21.85.","news_type":1,"symbols_score_info":{"CELU":0.9}},"isVote":1,"tweetType":1,"viewCount":950,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":false}